Literature DB >> 27789221

(Z)-ligustilide increases ferroportin1 expression and ferritin content in ischemic SH-SY5Y cells.

Yun-Ting Zhang1, Fei-Mi Li2, Yi-Zhen Guo1, Li-Rong Jiang1, Juan Ma2, Ya Ke3, Zhong-Ming Qian4.   

Abstract

The mechanisms involved in the antioxidant and anti-apoptotic properties of (Z)-ligustilide (LIG) are not fully elucidated. Based on the accumulated data, we hypothesized that LIG might be able to reduce ischemia/reperfusion-induced increase in brain iron by regulating expression of iron transport proteins. We therefore investigated the effects of LIG on iron uptake protein transferrin receptor 1, iron exporter protein ferroportin 1, iron storage protein ferritin light chain and also hypoxia inducible factor-1 alpha (HIF-1 alpha) in oxygen-glucose deprivation/reoxygenation (OGD/R)-treated SH-SY5Y cells, using Western blot analysis. We demonstrated that LIG completely reversed the OGD/R-induced reduction of ferroportin 1, increased ferritin light chain content, and also suppressed the OGD-induced increase in HIF-1 alpha in SH-SY5Y cells. These findings imply that LIG might reduce the OGD/R-induced increase in brain iron by promoting cell iron release and iron corporation into ferritin, and also by inhibiting the HIF-1 alpha-induced increase in transferrin-bound iron uptake and iron accumulation in the brain, consequently attenuating iron-mediated free radical formation, oxidative stress and apoptosis. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (Z)-ligustilide (LIG); Antioxidant and anti-apoptosis; Hypoxia inducible factor-1 alpha (HIF-1 alpha); Iron metabolism proteins; Oxygen-glucose deprivation/reoxygen (OGD/R); SH-SY5Y cells

Mesh:

Substances:

Year:  2016        PMID: 27789221     DOI: 10.1016/j.ejphar.2016.10.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Experimental study on the clinical effects of Xiaoru Sanjie Jiaonang on mammary glands hyperplasia and ki-67.

Authors:  Zi-Hao Zheng; Lin Liu; Shi-Fang Zou; Yu-Ting Xu; Cui-Cui Chen; Wen-Long Liang; Bao-Liang Guo; Yu Wang; Kai-Yuan Zhu; Jie-Na Liu; Dan-Dan Xu; Ji-Yan Wang; Jia-Yan Lin; Li Liu; Jian Guo Zhang; Xi Chen
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

2.  Ligustilide attenuates nitric oxide-induced apoptosis in rat chondrocytes and cartilage degradation via inhibiting JNK and p38 MAPK pathways.

Authors:  Yan Zhou; Jianghua Ming; Yaming Li; Ming Deng; Qing Chen; Yonggang Ma; Zhonghui Chen; Yubiao Zhang; Shiqing Liu
Journal:  J Cell Mol Med       Date:  2019-02-15       Impact factor: 5.310

3.  Ligustilide improves aging-induced memory deficit by regulating mitochondrial related inflammation in SAMP8 mice.

Authors:  Wen-Li Zhu; Jia-Yi Zheng; Wei-Wu Cai; Zhao Dai; Ben-Yue Li; Ting-Ting Xu; Hao-Fei Liu; Xiao-Qi Liu; Su-Fen Wei; Yi Luo; Hong Wang; Hua-Feng Pan; Qi Wang; Shi-Jie Zhang
Journal:  Aging (Albany NY)       Date:  2020-02-16       Impact factor: 5.682

4.  Z-Ligustilide Ameliorates Diabetic Rat Retinal Dysfunction Through Anti-Apoptosis and an Antioxidation Pathway.

Authors:  Bing Yang; Guobin Ma; Yang Liu
Journal:  Med Sci Monit       Date:  2020-10-04

5.  Therapeutic effect of a histone demethylase inhibitor in Parkinson's disease.

Authors:  Ming-Dao Mu; Zhong-Ming Qian; Sheng-Xi Yang; Kang-Lin Rong; Wing-Ho Yung; Ya Ke
Journal:  Cell Death Dis       Date:  2020-10-28       Impact factor: 8.469

6.  Ligustilide modulates oxidative stress, apoptosis, and immunity to avoid pathological damages in bleomycin induced pulmonary fibrosis rats via inactivating TLR4/MyD88/NF-KB P65.

Authors:  Shu Luo; Junzuo Gong; Xiaoping Cao; Shiping Liu
Journal:  Ann Transl Med       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.